Iwona Ben-Skowronek1. 1. Department of Pediatric Endocrinology and Diabetology, Medical University, 20-093 Lublin, Poland.
Abstract
(1) Background: IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-linked) syndrome characterizes a complex autoimmune reaction beginning in the perinatal period, caused by a dysfunction of the transcription factor forkhead box P3 (FOXP3). (2) Objectives: Studies have shown the clinical, immunological, and molecular heterogeneity of patients with IPEX syndrome. The symptoms, treatment, and survival were closely connected to the genotype of the IPEX syndrome. Recognition of the kind of mutation is important for the diagnostics of IPEX syndrome in newborns and young infants, as well as in prenatal screening. The method of choice for treatment is hematopoietic stem cell transplantation and immunosuppressive therapy. In children, supportive therapy for refractory diarrhea is very important, as well as replacement therapy of diabetes mellitus type 1 (DMT1) and other endocrinopathies. In the future, genetic engineering methods may be of use in the successful treatment of IPEX syndrome. (3) Conclusions: The genetic defects determine a diagnostic approach and prognosis, making the knowledge of the genetics of IPEX syndrome fundamental to introducing novel treatment methods.
(1) Background: IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-linked) syndrome characterizes a complex autoimmune reaction beginning in the perinatal period, caused by a dysfunction of the transcription factor forkhead box P3 (FOXP3). (2) Objectives: Studies have shown the clinical, immunological, and molecular heterogeneity of patients with IPEX syndrome. The symptoms, treatment, and survival were closely connected to the genotype of the IPEX syndrome. Recognition of the kind of mutation is important for the diagnostics of IPEX syndrome in newborns and young infants, as well as in prenatal screening. The method of choice for treatment is hematopoietic stem cell transplantation and immunosuppressive therapy. In children, supportive therapy for refractory diarrhea is very important, as well as replacement therapy of diabetes mellitus type 1 (DMT1) and other endocrinopathies. In the future, genetic engineering methods may be of use in the successful treatment of IPEX syndrome. (3) Conclusions: The genetic defects determine a diagnostic approach and prognosis, making the knowledge of the genetics of IPEX syndrome fundamental to introducing novel treatment methods.
Authors: I Kobayashi; R Shiari; M Yamada; N Kawamura; M Okano; A Yara; A Iguchi; N Ishikawa; T Ariga; Y Sakiyama; H D Ochs; K Kobayashi Journal: J Med Genet Date: 2001-12 Impact factor: 6.318
Authors: Hong Zhan; Jo Sinclair; Stuart Adams; Catherine M Cale; Simon Murch; Lucia Perroni; Graham Davies; Persis Amrolia; Waseem Qasim Journal: Pediatrics Date: 2008-03-03 Impact factor: 7.124
Authors: Yongqing Wu; Madhuri Borde; Vigo Heissmeyer; Markus Feuerer; Ariya D Lapan; James C Stroud; Darren L Bates; Liang Guo; Aidong Han; Steven F Ziegler; Diane Mathis; Christophe Benoist; Lin Chen; Anjana Rao Journal: Cell Date: 2006-07-28 Impact factor: 41.582
Authors: Laura Passerini; Sara Di Nunzio; Silvia Gregori; Eleonora Gambineri; Massimiliano Cecconi; Markus G Seidel; Giantonio Cazzola; Lucia Perroni; Alberto Tommasini; Silvia Vignola; Luisa Guidi; Maria G Roncarolo; Rosa Bacchetta Journal: Eur J Immunol Date: 2011-03-14 Impact factor: 5.532
Authors: David G Ousterout; Pablo Perez-Pinera; Pratiksha I Thakore; Ami M Kabadi; Matthew T Brown; Xiaoxia Qin; Olivier Fedrigo; Vincent Mouly; Jacques P Tremblay; Charles A Gersbach Journal: Mol Ther Date: 2013-06-04 Impact factor: 11.454